Novo Nordisk ASHAM:NOVA +2.90%84 Buyback Yield % is 0.17 as of Jul. 06, 2026, which is 89% below its 10-year median of 1.57. GuruFocus rates HAM:NOVA with a GF Score™ of 84/100 and a GF Value™ of €121.46 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 291 Drug Manufacturers companies, Novo Nordisk AS ranks better than 73.88% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for Novo Nordisk AS's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HAM:NOVA vs LLY, JNJ, ABBV: Buyback Yield % Comparison
For the Drug Manufacturers - General subindustry, Novo Nordisk AS's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Novo Nordisk AS Buyback Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Novo Nordisk AS's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Novo Nordisk AS's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Novo Nordisk AS (HAM:NOVA) has a Buyback Yield % of 0.17 as of Jul. 06, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Novo Nordisk AS and its competitors. This is 89% below median its historical median of 1.57. Over the past decade, Novo Nordisk AS's Buyback Yield % has ranged from 0.10 to 2.55. According to the industry distribution chart, Novo Nordisk AS ranks #76 out of 291 companies in the Drug Manufacturers industry, placing it in the top 26.1%.
Is Novo Nordisk AS's Buyback Yield % too high?
Novo Nordisk AS's current Buyback Yield % of 0.17 is 89% below median its 10-year median of 1.57. Over the past 10 years, this metric has ranged from a low of 0.10 to a high of 2.55. Based on the distribution chart, Novo Nordisk AS ranks #76 out of 291 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Novo Nordisk AS has a GF Score™ of 84/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Novo Nordisk AS's Buyback Yield % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Novo Nordisk AS ranks #76 out of 291 companies for Buyback Yield %. This puts Novo Nordisk AS in the upper half of its industry. Historically, Novo Nordisk AS's own Buyback Yield % has ranged from 0.10 to 2.55 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Drug Manufacturers company?
A good Buyback Yield % depends on the Drug Manufacturers industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Novo Nordisk AS and its competitors. Novo Nordisk AS's current Buyback Yield % is 0.17, which is 89% below median its own 10-year median of 1.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novo Nordisk AS stock overvalued right now?
Based on GuruFocus' analysis, Novo Nordisk AS (HAM:NOVA) is currently considered Significantly Undervalued. The stock's GF Value™ is €121.46, compared to a current price of €43.94 — trading 63.8% below its estimated fair value. The current Buyback Yield % is 0.17, which is 89% below median its 10-year median of 1.57. Novo Nordisk AS's overall GF Score™ is 84/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Novo Nordisk AS (HAM:NOVA), the current Buyback Yield % is 0.17 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Novo Nordisk AS (HAM:NOVA) Overvalued in 2026?
Based on GuruFocus' analysis, Novo Nordisk AS stock appears to be undervalued.
The current stock price of €43.94 is trading 63.8% below its estimated GF Value™ of €121.46.
GuruFocus considers Novo Nordisk AS to be Significantly Undervalued.
Key valuation signals for HAM:NOVA:
Buyback Yield %: 0.17 (89% below median its 10-year median of 1.57)
GF Value™: €121.46 vs. price of €43.94 (63.8% below fair value)
No single metric tells the full story. See the HAM:NOVA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
84GF Score
Get the complete analysis for HAM:NOVA
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:NOVA has been successfully added to your 
